Gilead exec’s flee after milking the health care system

  • Executives at Gilead are leaving a sinking ship.
  • Sales of a breakthrough drug they purchased through the acquisition of Kite Pharma  have failed to match expectations.
  • Gilead charges thousands of dollars for a drug for their AIDS drug, but competition is creeping in.
  • Since Truvada was approved for HIV prevention six years ago, its average wholesale price has increased by about 45 percent.
  • Without more drugs to buy Gilead’s stock has been declining.

Continue reading

Pharma gives the middle finger to patients

KEY TAKEAWAY:Gilead, which recently acquired Kite Pharma in an all cash deal, said the list price for Yescarta, which is to be administered just once to each patient, would be $373,000. The cost is supposed to make us feel good because the price is well below that of the first drug in this new class such as $475,000 for Novartis’s  Kymriah.

Continue reading